State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Yingxin Street 100, Xuanwu District, Beijing 100052, People's Republic of China.
Biochem Biophys Res Commun. 2009 Dec 25;390(4):1305-8. doi: 10.1016/j.bbrc.2009.10.142. Epub 2009 Oct 29.
The neuraminidase inhibitor oseltamivir has been identified to have significant anti-influenza activity in clinical practice. However, its efficacy has not been verified in enough subtypes of influenza A virus, particularly, the current pandemic virus, H1N1. In vitro, using our influenza pseudotyped particle system, oseltamivir displayed significant inhibitory effects on viral NA activity and pp release. Conversely, a boosting effect on viral infection was observed, particularly with the 2009 H1N1 pp at oseltamivir concentrations above 0.025muM. Further testing on two wild 2009 H1N1 virus strains, A/California/07/09 and A/Sichuan/1/09, as well as a seasonal flu virus, A/Baoan/51/2008, confirmed these findings.
神经氨酸酶抑制剂奥司他韦在临床实践中被发现具有显著的抗流感活性。然而，它在足够多的甲型流感病毒亚型中的疗效尚未得到验证，特别是目前的大流行病毒 H1N1。在体外，使用我们的流感假病毒粒子系统，奥司他韦对病毒 NA 活性和 pp 释放显示出显著的抑制作用。相反，在奥司他韦浓度高于 0.025μM 的情况下，观察到对病毒感染的促进作用，特别是对于 2009 年 H1N1 pp。对两个野生 2009 年 H1N1 病毒株 A/California/07/09 和 A/Sichuan/1/09 以及季节性流感病毒 A/Baoan/51/2008 的进一步测试证实了这些发现。
